Prosecution Insights
Last updated: May 29, 2026

Pharma Mar S A

4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

4
Total Pending OAs
4
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (25%)
1
Easy (25%)
2
Unknown (50%)

Rejection Statute Mix

BucketCases
§103 only1 (25%)
§112 only1 (25%)
No statute on record2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
TOWNSLEY, SARA ELIZABETH 1 25.3% +48.6%
ROBINSON, MIKHAIL O'DONNEL 1 56.8% +41.6%
HELLMAN, KRISTINA M 1 66.0% +54.3%
HA, JULIE 1 75.6% +44.4%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18560991 DOSAGE REGIMENS FOR ECUBECTEDIN TOWNSLEY, SARA ELIZABETH 14d

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17908532 COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS HA, JULIE 58d overdue
17908524 COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION HELLMAN, KRISTINA M 4d overdue
18560991 DOSAGE REGIMENS FOR ECUBECTEDIN TOWNSLEY, SARA ELIZABETH 14d
17920000 DRUG ANTIBODY CONJUGATES ROBINSON, MIKHAIL O'DONNEL 35d

Top Art Units

Art UnitApps
1654 2
1629 1
1627 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18560991 DOSAGE REGIMENS FOR ECUBECTEDIN TOWNSLEY, SARA ELIZABETH 1629 Other Non-Final OA 14d Pending Nov 15, 2023
17920000 DRUG ANTIBODY CONJUGATES ROBINSON, MIKHAIL O'DONNEL 1627 §112 Non-Final OA 35d Pending Oct 19, 2022
17908524 COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION HELLMAN, KRISTINA M 1654 Other Non-Final OA 4d overdue Pending Aug 31, 2022
17908532 COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS HA, JULIE 1654 §103 Non-Final OA 58d overdue Pending Aug 31, 2022

Managing Pharma Mar S A's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month